Design and Computational Evaluation of Quinazolinone Hydrazine Schiff Base Derivatives as EGFR Inhibitors
This study computationally evaluates a series of quinazolinone-based hydrazine Schiff base derivatives as promising EGFR inhibitors, demonstrating that Compound 5 exhibits superior binding affinity, pharmacokinetic properties, and electronic characteristics compared to the standard drug erlotinib.